To investigate the role of activated PPARγ in the context of heterotypic signaling working in tumor-stroma interactions, we examined the ability of BRL to reduce CAF-induced effects through CXCR4 axis inhibition in breast cancer cells. This evidence concerns the gene BRD1 and neoplasm.